BE636381A - - Google Patents
Info
- Publication number
- BE636381A BE636381A BE636381DA BE636381A BE 636381 A BE636381 A BE 636381A BE 636381D A BE636381D A BE 636381DA BE 636381 A BE636381 A BE 636381A
- Authority
- BE
- Belgium
- Prior art keywords
- propyl
- monoglyceride
- anthranilate
- quinoline
- dioxolane
- Prior art date
Links
- 241000790917 Dioxys <bee> Species 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- QNGUPQRODVPRDC-UHFFFAOYSA-N 7-chloroquinoline Chemical compound C1=CC=NC2=CC(Cl)=CC=C21 QNGUPQRODVPRDC-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- QYGHESHPPSSONP-UHFFFAOYSA-N propyl 2-aminobenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1N QYGHESHPPSSONP-UHFFFAOYSA-N 0.000 claims description 5
- FEIDDCIQBWFLGQ-UHFFFAOYSA-N propyl 2-nitrobenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1[N+]([O-])=O FEIDDCIQBWFLGQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 150000007530 organic bases Chemical group 0.000 claims description 4
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 3
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims description 2
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000875 corresponding Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 nitrobenzoyl Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HTKGKUISLUERQX-UHFFFAOYSA-N 2-[(7-chloroquinolin-4-yl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 HTKGKUISLUERQX-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BOHGAOWOIJMTPZ-UHFFFAOYSA-N 1,3-dioxolan-4-ylmethanol Chemical compound OCC1COCO1 BOHGAOWOIJMTPZ-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-M 2-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-M 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- YTWFQMHVBZSCIM-UHFFFAOYSA-N [propylsulfanyl-[(2-sulfanylidene-1,3-benzothiazol-3-yl)methylsulfanyl]methylidene]cyanamide Chemical class C1=CC=C2SC(=S)N(CSC(SCCC)=NC#N)C2=C1 YTWFQMHVBZSCIM-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-M anthranilate Chemical compound NC1=CC=CC=C1C([O-])=O RWZYAGGXGHYGMB-UHFFFAOYSA-M 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE636381A true BE636381A (ko) |
Family
ID=202435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE636381D BE636381A (ko) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE636381A (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2158234A1 (ko) * | 1971-10-19 | 1973-06-15 | Abbott Lab |
-
0
- BE BE636381D patent/BE636381A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2158234A1 (ko) * | 1971-10-19 | 1973-06-15 | Abbott Lab |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1061346A (fr) | Procede d'obtention de nouvelles dihydropyridines | |
| CA1116635A (fr) | Procede de preparation de nouveaux derives de la benzene propanamine et de leurs sels | |
| EP0779284B1 (fr) | Nouveaux dérivés de 2-naphthamides et leurs applications thérapeutiques comme agonistes des récepteurs D3 | |
| CH624952A5 (ko) | ||
| JP5006311B2 (ja) | 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法 | |
| FR2493315A1 (fr) | Derive de piperazine, procede pour sa preparation et composition analgesique en contenant | |
| US3766259A (en) | Preparation of 1-aryl-3-indenyl acetic acids | |
| CH649994A5 (fr) | Derives du 4h-1,2,4-triazole, procedes de preparation et compositions les renfermant. | |
| CH630606A5 (en) | Phenylamidine derivatives useful especially in therapeutics | |
| CH619935A5 (ko) | ||
| CH616647A5 (ko) | ||
| CA1139763A (fr) | Procede d'obtention de nouveaux aryltrifluoroethanols | |
| CA1042905A (fr) | Procede de preparation de nouveaux azabicycloalcanes disubstitues | |
| BE636381A (ko) | ||
| EP0214004B1 (fr) | Dérivés de l'acide 4-OH quinoléine carboxylique substitué en 2 par un groupement dihydroxylé éventuellement éthérifié ou estérifié, procédé et inter-médiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
| FR2551063A1 (fr) | Nouveaux dimethyl-2,5 pyrroles, leur procede de preparation et leur application en therapeutique | |
| CA1088099A (fr) | Procede de preparation de nouveaux alcoxy anilides et composes ainsi obtenus | |
| CA1091249A (fr) | Procede de preparation de nouvelles n-acyl glutamines et les nouveaux produits ainsi obtenus | |
| CA1076117A (fr) | Procede d'obtention de nouveaux ethers aryliques et les produits en resultant | |
| FR2547822A1 (fr) | Acylpiperazinoquinazolines substituees utiles comme medicaments et procede pour leur preparation | |
| CA1063619A (fr) | Procede de preparation de nouveaux acides benzylamino alcanoiques et les produits qui en resultent | |
| FR2503140A1 (fr) | Acides biphenyl-4 oxo-4 methylene-3 butyriques, leur procede de preparation et leur utilisation comme medicaments | |
| EP0266246A1 (fr) | Dérivés d'imidazo[4,5-b]pyridinone-2, leur préparation et leur application en thérapeutique | |
| EP0100257B1 (fr) | Nouveaux dérivés aminoalkyl naphtaléniques, leurs sels d'addition d'acide et le procédé de préparation ainsi que l'application en thérapeutique de ces dérivés et sels | |
| EP0157762B1 (fr) | Nouvelles piperidinoguanidines substituees, leur procede de preparation et les compositions pharmaceutiques en renfermant |